secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELUTIA INC. (ELUT)
CIK:        0001708527
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001104659-25-088481
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline
--------------------------------------------------------------------------------

- Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
- Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.
- Transaction expected to close in Q4 2025, subject to customary closing conditions.
- Elutia to focus resources on SimpliDerm franchise and drug-eluting pipeline in the $1.5B US breast reconstruction market.
- BofA Securities served as financial advisor to Elutia on the sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925088481/0001104659-25-088481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708527/000110465925088481/tm2525591d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-088481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer